Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court
This article was originally published in The Tan Sheet
Executive Summary
A recent British Medical Journal study does not support McNeil Consumer & Specialty Pharmaceuticals' advertising claims that 81 mg aspirin "is just as effective as 325 mg in reducing the risk of recurrent heart attacks," Bayer says in a lawsuit filed in New York federal court April 25
You may also be interested in...
Aleve “Doctor Recommended” Ad Claim Has No “Reasonable Basis” – NAD
Bayer Consumer Care should modify TV ads comparing the company's Aleve analgesic with McNeil Consumer and Specialty Pharmaceuticals' Tylenol "to avoid conveying a 'doctor recommended message,'" the National Advertising Division of the Council of Better Business Bureaus says
McNeil compliance with NAD
Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...
Aspirin CVD Indication On OTC Labeling Urged By FDA’s Jenkins
A cardiovascular disease prevention indication on OTC aspirin could be on the horizon, particularly if industry heeds FDA's invitation to propose such a change to the internal analgesics monograph